Immune Regulation of COVID-19 Infection in Cancer and Autoimmunity

摘要： 埃默里U 54 SeroNET U 54计划是一个多学科计划，汇集了 经验丰富的调查人员团队，以解决与豁免权有关的基本问题， SARS CoV-2，特别是癌症和自身免疫患者。球队有一个很长的 在病毒感染背景下的基础和转化研究方面的既往工作记录， 疫苗与癌症该计划包括3个相互作用的项目和两个基本的 除了行政核心之外。项目1的研究（由Sanz领导）将研究 SARS患者中SARS CoV-2特异性效应B细胞应答的生物学 自身免疫，特别关注滤泡外B细胞途径。研究项目 2（由Sekaly和Wrammert领导）将研究炎症环境在调节 抗病毒免疫和长期记忆反应的发展。研究 项目3（由Dhodapkar和Ahmed领导）将侧重于研究具体的 癌症治疗，特别是B/浆细胞患者的B/浆细胞耗竭治疗 细胞恶性肿瘤和肺癌患者的免疫检查点阻断。这些 这些研究还将为研究未来SARS CoV-2的免疫反应奠定基础 自身免疫性疾病患者以及癌症患者的疫苗。将程序 由活跃的核心（由Roback和Neish领导）提供支持，这些核心具有以下方面的经验： 监测对SARS CoV-2的免疫力。这项计划不仅提供基本的 深入了解COVID的免疫发病机制，同时也为该联盟提供 接触具有较高COVID相关死亡风险的独特患者人群。

Abstract: The Emory U54 SeroNET U54 program is a multidisciplinary program that brings together experienced team of investigators to tackle fundamental issues relating to immunity to SARS CoV-2, particular in patients with cancer and autoimmunity. The team has a long track record of prior work in basic and translational studies in the setting of viral infections, vaccines and cancer. The program consists of 3 interacting projects and two essential cores in addition to the administrative core. Studies in project 1 (led by Sanz) will study the biology of SARS CoV-2 specific effector B cell responses in patients with autoimmunity, with a particular focus on extrafollicular B cell pathway. Studies in project 2 (led by Sekaly and Wrammert) will study the role of inflammatory milieu in regulating antiviral immunity and in the development of long term memory responses. Studies in project 3 (led by Dhodapkar and Ahmed) will focus on studying the impact of specific cancer therapies, in particular B/plasma cell depleting therapies in patients with B/plasma cell malignancies, and immune checkpoint blockade in patients with lung cancer. These studies will also set the stage for studying immune responses to future SARS CoV-2 vaccines in patients with autoimmunity as well as cancer patients. The programs are supported by active cores (led by Roback and Neish) which have experience with monitoring immunity to SARS CoV-2. Together, this program will not only provide basic insights into immune-pathogenesis of COVID, but also provide the consortium with access to unique patient populations at higher risk of COVID-related mortality.